China (Mainland)
High Quality mirabegron CAS NO.223673-61-8
- FOB Price: USD: 1.00-1.00 /Gram Get Latest Price
- Min.Order: 1 Gram
- Payment Terms: L/C,D/A,D/P,T/T,
- Available Specifications:
1(1-2)Gram
- Product Details
Keywords
- 223673-61-8
- mirabegron
- mirabegron Price
Quick Details
- ProName: High Quality mirabegron
- CasNo: 223673-61-8
- Molecular Formula: C21H24N4O2S
- Appearance: White powder
- Application: pharmaceutical intermediates
- DeliveryTime: Qingdao Port
- PackAge: 1kg or 25Kg drum
- Port: QIngdao Port
- ProductionCapacity: 3000 Metric Ton/Year
- Purity: 98% HPLC
- Storage: Store in dry, dark and ventilated plac...
- Transportation: By air or by sea. Prompt delivery
- LimitNum: 1 Gram
- Moisture Content: See data sheet
- Samples: Available
Superiority
We promise our customer following items
1.Reasonable price:
2.Low moq:No worry about the low moq, our moq is 1 gram or lower.
3.Good and efficient service,Fast Delivery
4.Super-good quality
Contact us
If you have any further questions or need a sample,Please do not hesitate to contact us.
Jessica | Senior Sales | Qingdao Sigma chemical Co.,Ltd
| Address:No 70,Shandong Road,Qingdao city,China
Details
| Product name | Mirabegron(YM 178) |
| English Synonyms | 4-Thiazoleacetamide, 2-amino-N-(4-(2-(((2R)-2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)-;Mirabegron;N-(4-(2-(2-hydroxy-2-phenylethylamino)ethyl)phenyl)-2-(2-aminothiazol-4-yl)acetamide;2-AMino-N-[4-[2-[[(2R)-2-hydroxy-2-phenyl-ethyl]aMino]-ethyl]phenyl]-4-thiazoleacetaMide;2-(2-aMino-1,3-thiazol-4-yl)-N-(4-{2-[(2-hydroxy-2-phenylethyl)aMino]ethyl}phenyl)acetaMide;(2R)-2-(2-AMinothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)aMino]ethyl]acetic Acid Anilide;YM 178;Mirabegron(YM 178) |
| MOQ | 10 vials |
| CAS | 223673-61-8 |
| Formula | C21H24N4O2S |
| MW | 396.506 |
| EINECS | 1592732-453-0 |
| Purity | 99% |
| Appearance | White Powder |
| Grade | Pharmaceutical Grade |
| Storage | -20°C Freezer |
| Usage | Selective β3-adrenergic receptor agonist for overactive bladder |
Overactive bladder (OAB), defined by the International Continence Society as urgency with or without urinary incontinence, usually associated with frequency and nocturia. is a multifactorial and common health disorder associated with detrimental effects on quality of life and huge economic burden.
Irrespective of the pathophysiology, the aim of treatment of OAB is to obtain symptom relief without affecting the empty phase of the micturition cycle. Current first-line treatment relies mainly on conservative therapeutic strategies, such as behavioural therapies, functional electrical stimulation, clean intermittent catheterization and pharmacological treatment. Second-line treatment options in refractory patients are neuromodulation, botulinum toxin and surgery. Antimuscarinic drugs are US Food and Drug Adminstration (FDA)-approved medications for OAB and represent the mainstay of pharmacological treatment. Unfortunately, antimuscarinics are not always effective in controlling OAB symptoms and rarely 'cure' OAB. Furthermore, bothersome adverse effects (AEs), including dry mouth, nausea, constipation and central nervous system AEs, due to their lack of bladder selectivity, cause poor long-term adherence to treatment.
Recent advances in the understanding of the physiopathology of OAB have driven a huge amount of basic and clinical research into novel pharmacological compounds. Among potential novel peripherally acting drugs, β3-adrenoceptor (AR) agonists appear very promising.
d sulfuric acid.
